XiaobingYang China

Wcn26 Post edited Speaker Card

29 March 2026

Time

Session

2:10 p.m.

3:10 p.m.

HIT! High Impact Clinical Trials 3 - In IgA Nephropathy

Sydney Tang Chair Hong Kong, China

EFFICACY AND SAFETY RESULTS OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY ON SODIUM‚ÄÌGLUCOSE CO-TRANSPORTER 2 INHIBITORS: PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL (ASSIST)

HiddoLambers Heerspink Speaker Netherlands
EFFICACY AND SAFETY OF A TARGETED-RELEASE FORMULATION OF BUDESONIDE (HR19042 CAPSULES) IN PATIENTS WITH PRIMARY IGA NEPHROPATHY: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER, PLACEBO-CONTROLLED PHASE 2/3 TRIAL

XiaobingYang Speaker China
EVALUATING THE EFFECT OF SPARSENTAN VS IRBESARTAN ON URINE INFLAMMATORY AND PROFIBROTIC BIOMARKERS IN THE PHASE 3 PROTECT TRIAL OF PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY
EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): FINAL 24-MONTH RESULTS FROM THE PHASE III APPLAUSE-IGAN STUDY

VladoPerkovic Speaker Australia

Main Hall